Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: ALIMTA plus Epirubicin
Sponsor: Eli Lilly and Company